TGFB1 and idiopathic pulmonary fibrosis: 1999). Targeting of αvβ6 integrin leads to local inhibition of TGF‐β activation in IPF lungs, and a clinical trial using monoclonal antibody against αvβ6 integrin is currently underway (NCT01371305) (Horan et al. 2008).